LN-145

Unassigned

New Medicines

Recurrent, metastatic or persistent cervical cancer

Information

Advanced therapy medicinal product (ATMP)
Iovance Biotherapeutics
Iovance Biotherapeutics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes

Category

Autologous cell therapy consisting of tumour-infiltrating lymphocytes (TIL) isolated from the patient tumour, that are expanded ex vivo, and infused back into the patient followed by interleukin-2 (IL-2) administration
There were 3,126 new cases of cervical cancer in 2015 in the UK [1]. Around 30% of cervical cancers are detected through cervical screening in the UK. Cervical cancer is more common in those aged 25-34 years [2].
Recurrent, metastatic or persistent cervical cancer
Intravenous infusion